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Signaling via heterotrimeric G proteins plays a crucial role in modulating the responses
of striatal neurons that ultimately shape core behaviors mediated by the basal ganglia cir-
cuitry, such as reward valuation, habit formation, and movement coordination. Activation
of G protein-coupled receptors (GPCRs) by extracellular signals activates heterotrimeric G
proteins by promoting the binding of GTP to their α subunits. G proteins exert their effects
by inﬂuencing the activity of key effector proteins in this region, including ion channels,
second messenger enzymes, and protein kinases. Striatal neurons express a staggering
number of GPCRs whose activation results in the engagement of downstream signaling
pathways and cellular responses with unique proﬁles but commonmolecular mechanisms.
Studies over the last decade have revealed that the extent and duration of GPCR signaling
are controlled by a conserved protein family named regulator of G protein signaling (RGS).
RGS proteins accelerate GTP hydrolysis by the α subunits of G proteins, thus promoting
deactivation of GPCR signaling. In this review, we discuss the progress made in under-
standing the roles of RGS proteins in controlling striatal G protein signaling and providing
integration and selectivity of signal transmission.We review evidence on the formation of
a macromolecular complex between RGS proteins and other components of striatal sig-
naling pathways, their molecular regulatory mechanisms and impacts on GPCR signaling in
the striatum obtained from biochemical studies and experiments involving genetic mouse
models. Special emphasis is placed on RGS9-2, a member of the RGS family that is highly
enriched in the striatum and plays critical roles in drug addiction and motor control.
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STRIATAL G PROTEIN SIGNALING: AN OVERVIEW
Striatum is a large part of the subcortical basal ganglia system
consisting of caudate and putamen nuclei in the dorsal side that
receives dopaminergic input from substantia nigra and nucleus
accumbens on the ventral side that receives dopaminergic input
from the ventral tegmental area. In addition, both ventral and
dorsal striatum receive major glutamatergic input from cortical
areas as well as inputs from other nuclei of basal ganglia such as
subthalamic nucleus and the external globus pallidus (Graybiel,
2000).
Striatal neurons play critical roles in initiating and maintaining
movement, mood control, reward behavior, and drug addiction
(Graybiel, 2000; Kreitzer and Malenka, 2008). Dysfunctions in
the neurocircuitry of the striatum have been implicated in the
development of a wide range of disorders, including Parkinson’s
disease (Picconi et al., 2005), Huntington’s disease (Cepeda et al.,
2007), depression (Nestler and Carlezon, 2006), and drug addic-
tion (Everitt and Robbins, 2005). The striatum contains a rela-
tively heterogeneous neuronal population. Medium spiny neurons
(MSNs) are the most abundant type, accounting for 90–95% of
neurons in this region (Graveland and DiFiglia, 1985). Despite
their morphological similarities, MSNs are categorized into two
different subtypes based on differences in their gene expression
and axonal projections (Gerfen et al., 1990; Surmeier et al., 2007;
Heiman et al., 2008). The ﬁrst group, striatonigral MSNs, selec-
tively expresses dynorphin and dopamine D1 receptors and sends
projections directly to basal ganglia output nuclei. The second
group, striatopallidal MSNs, selectively expresses enkephalin and
dopamine D2 receptors and sends axons to the external globus
pallidus. In addition to MSNs, the striatum contains small pop-
ulations of giant cholinergic interneurons, easily distinguished by
their large cell bodies and tonic activities (Zhou et al., 2002), as
well as parvalbumin and calretinin interneurons (Cicchetti et al.,
2000).
One of the striking features of the striatum is thewide variety of
neurotransmitter inputs that converge onto striatal neurons. The
ﬁrst major excitatory input is provided by glutamatergic affer-
ents, most notably from the cerebral and prefrontal cortexes but
also from several other brain regions, such as the thalamus, amyg-
dala, and hippocampus (McGeorge and Faull, 1989; Bolam et al.,
2000). The second major input to the striatum is provided by
neurons from the substantia nigra and ventral tegmental area
that release dopamine (Smith and Kieval, 2000). The glutamate
and dopamine systems intimately overlap, and their interaction is
thought to be essential for striatal signaling (for reviews see Gray-
biel, 1990; Chase and Oh, 2000; David et al., 2005). In addition,
the striatum receives several other neurotransmitter inputs that
play important modulatory roles. Despite their scarcity, striatal
cholinergic interneurons densely innervate both the ventral and
dorsal striatum; they form an extensive local axon collateral sys-
tem, making contacts with MSNs and other interneurons (Koos
and Tepper, 2002; Zhou et al., 2002). Changes in the amount
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of acetylcholine (ACh) released by these neurons are crucial for
determining the activity of the striatal output neurons (Calabresi
et al., 2000). Striatal neurons also receive substantial projections
from noradrenergic (Nestler et al., 1999; Sara, 2009) and seroton-
ergic neurons (Azmitia and Segal, 1978; Moukhles et al., 1997)
located in the locus coeruleus and the dorsal raphe nuclei, respec-
tively. Several locally synthesized and released neuromodulators
also play important roles in striatal signaling. These neuromodula-
tors include endogenous opioids, such as endorphins, enkephalins,
dynorphins, and orphanin FG, which are found in abundance in
the nucleus accumbens and the surrounding ventral striatum and
are known to be involved in motivational aspects of behavior (Van
Ree et al., 2000; Kelley et al., 2002), as well as endocannabinoids,
which act in a retrograde manner to inhibit neurotransmitter
release (Bisogno et al., 2005; Basavarajappa, 2007). Adenosine,
a ubiquitous homeostatic substance released from most cells,
including neurons and glia (Cunha, 2001; Dunwiddie and Masino,
2001), has important neuromodulatory effects on dopamine and
glutamate transmission in the striatum. Presynaptically, adenosine
inhibits or facilitates transmitter release while causing hyperpo-
larization or depolarization in postsynaptic neurons (Dunwiddie
and Masino, 2001; Ribeiro et al., 2002). Finally, MSNs signal by
releasing the inhibitory neurotransmitter GABA (Bolam et al.,
2000; Graybiel, 2000). While their projections target a range of
effector nuclei in the mesolimbic system, they also form extensive
local contacts with neighboring neurons, making GABA impor-
tant for regulating the spiking timing of spiny outputs (Tepper
et al., 2004).
Thus, multiple neurotransmitter systems act simultaneously in
the striatumbothpre andpostsynaptically to shapeneuronal activ-
ity. This creates an environment where individual neurons inte-
gratemultiple inputs that often act cooperatively to affect excitabil-
ity and the long-term adaptive effects that underlie their physio-
logical function. This organization places a signiﬁcant emphasis
on the principles and mechanisms of intracellular signaling path-
ways that interpret, coordinate, and integrate signals carried by
multiple neurotransmitters.
One of the central signaling systems that mediate the effects of
neurotransmitters is the seven-transmembraneGprotein-coupled
receptors (GPCRs). In the canonical pathway, upon binding
to neurotransmitter molecules, GPCRs undergo conformational
changes that activate their ability to catalyze the exchange of GDP
with GTP (Gilman, 1987; Pierce et al., 2002). From this per-
spective, GPCRs act as GDP/GTP guanine nucleotide exchange
factors (GEFs) for G proteins. G proteins comprise three subunits:
α, β and γ. GTP binding to the α subunit causes it to dissoci-
ate from the βγ complex. Both the active (GTP-bound) form of
Gα and free Gβγ interact with a range of downstream signaling
molecules (“effectors”) and modulate their activity to generate
cellular responses. Recent studies have also revealed an additional
G protein-independent signaling mechanism of GPCRs: neuro-
transmitter binding induces phosphorylation of GPCRs, followed
by the binding of an adaptor protein, β-arrestin, that recruits a
host of signaling factors to transmit the signal (Lefkowitz and
Shenoy, 2005; Lefkowitz et al., 2006; Premont and Gainetdinov,
2007). While the importance of this non-canonical GPCR sig-
naling pathway for striatal signaling is emerging, the scope of
our review is limited to the traditional G protein-based signaling
mechanisms.
Mammalian genomes contain more than 800 genes that encode
GPCRs (Lander et al., 2001;Venter et al., 2001), andmany different
types of GPCRs are expressed in striatal neurons (see Versatility
of the GPCR Repertoire in the Striatum). Despite such diver-
sity, all GPCRs transduce signals via a limited set of G proteins.
There are four subfamilies of Gα subunits (Gαs, Gαi/o, Gαq, and
Gα12) that have selective preferences for the activation of differ-
ent GPCR classes (Oldham and Hamm, 2008). However, many
GPCRs can couple to more than one Gα protein. Gα subunits
also show selectivity in their regulation of downstream effectors
(Gilman,1987).Canonically,Gαs andGαi proteins regulate adeny-
lyl cyclase,Gαq family proteins activate phospholipase Cβ (PLCβ),
and Gα12 protein control members of the RhoGEF superfamily
(Pierce et al., 2002; Oldham and Hamm, 2008). Four signal trans-
ducing beta subunits and 13 gamma subunits form constitutive
complexes with poorly understood selectivity and, when released
from the heterotrimer, can also regulate a range of effectors, most
notably phospholipases (PLCβ2), and ion channels (Dupre et al.,
2009). Signaling is terminated when the neurotransmitter disso-
ciates from the receptor; the receptor’s GEF activity is quenched,
and the GTP on the Gα subunit is hydrolyzed to allow reforma-
tion of the inactive Gαβγ heterotrimer and dissociates from the
effectors.
G protein-coupled receptor signaling pathways are organized
in a way that allows tremendous integration of signaling events
at the G protein level. The balance between reactions that lead
to activation or deactivation plays a central role in dictating
the extent of the effectors’ activity regulation and is ultimately
responsible for shaping neuronal responses. Intracellular factors
that regulate G protein activity status are, thus, expected to play
essential roles in controlling the responses of striatal neurons to
neurotransmitters.
VERSATILITY OF THE GPCR REPERTOIRE IN THE STRIATUM
Consistent with multiple neurotransmitter inputs, striatal neu-
rons utilize many GPCRs, which are abundantly expressed and
play essential roles in striatal physiology. It is extremely difﬁcult
to provide a comprehensive overview about all of the GPCR sys-
tems involved in the physiology of the striatal neurons. Several
orphan GPCRs for as yet unknown ligands are also present in the
region (Mizushima et al., 2000; Marazziti et al., 2007; Logue et al.,
2009). Our account below provides an overview of the GPCR sys-
tems that signiﬁcantly contribute to G protein activation and have
ﬁrmly established physiological roles (Table 1).
Dopamine receptors are perhaps the most studied GPCRs in
the striatum and have ﬁrmly established physiological roles (Jaber
et al., 1996; Missale et al., 1998; Glickstein and Schmauss, 2001;
El-Ghundi et al., 2007). Although all ﬁve dopamine receptors are
present in the striatum, the roles of D1R and D2R receptors have
received the greatest attention. Both D1R and D2R are abundantly
expressed in striatal neurons; however, they show remarkable seg-
regation among cell types. D1R is expressed in the striatonigral
MSNs, constituting the direct pathway, whereas D2R is expressed
in the striatopallidal or indirect pathway (Gerfen et al., 1990; Gray-
biel, 2000; Shuen et al., 2008;Matamales et al., 2009). D2Rs are also
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Table 1 | Major GPCRs and their downstream effectors in the striatum.
Receptor type G protein
coupling
Signaling effector(s) Reference
Dopamine D1, D5 Gαs(olf) cAMP/PKA,
L/P/Q-type Ca2+
channels
Surmeier et al. (1995), Lee et al. (2002), Iwamoto et al. (2003), Kim et al. (2006)
D2, D3, D4 Gαi/o cAMP/PKA, L-type
Ca2+ channel
Hernandez-Lopez et al. (2000), Lee et al. (2002), Iwamoto et al. (2003)
D1/D2 dimer Gαq PLCβ/PKC Lee et al. (2004), Hasbi et al. (2009)
Opioid μ, δ, κ Gαi/o cAMP/PKA, N-type
Ca2+ channel
Dhawan et al. (1996), Law et al. (2000), Spadoni et al. (2004)
Muscarinic M1, M3, M5 Gαq PLCβ/PKC Caulﬁeld and Birdsall (1998), Salah-Uddin et al. (2008)
M2, M4 Gαi/o cAMP/PKA, K+
channel
Akins et al. (1990), Gabel andNisenbaum (1999),Wess (2004), Ishii and Kurachi
(2006), Sanchez et al. (2009)
Metabotropic
glutamate
mGluR 1, 5 Gαq PLCβ/PKC Conn and Pin (1997), Ferre et al. (2002), Jong et al. (2009)
mGluR 2, 3,4, 7, 8 Gαi/o cAMP/PKA Prezeau et al. (1994), Conn and Pin (1997)
Adenosine A1, A3 Gαi/o cAMP/PKA,
N/P/Q-type Ca2+
channels
Ambrosio et al. (1996), Song et al. (2000), Fredholm et al. (2001)
A2 Gαs(olf) cAMP/PKA Lee et al. (2002)
Cannabinoid CB1, CB2 Gαi/o cAMP/PKA,
voltage-gated Ca2+
channel, K+ channel
Pertwee (1997), Felder and Glass (1998), Piomelli (2003)
Serotonin 5-HT1, 5 Gαi/o cAMP/PKA, K+
channel
Barnes and Sharp (1999), Di Matteo et al. (2008), Nichols and Nichols (2008)
5-HT2 Gαq PLCβ/PKC, K+ channel Barnes and Sharp (1999), Di Matteo et al. (2008), Nichols and Nichols (2008)
5-HT4, 6, 7 Gαs(olf) cAMP/PKA Barnes and Sharp (1999), Di Matteo et al. (2008), Nichols and Nichols (2008)
located presynaptically on dopaminergic terminals and participate
in the autoregulation of dopamine release (Jaber et al., 1996). A
small population of MSNs (∼5%) co-expresses both D1R and
D2R (Falk et al., 2006; Shuen et al., 2008), which have been shown
to form heterodimers (Lee et al., 2004). Remarkably, D1R–D2R
dimers can activate Gαq, creating an additional signaling modality
(Lee et al., 2004; Hasbi et al., 2009).
Our knowledge regarding the involvement of D3R, D4R, and
D5R is much more limited, in part due to their relatively low
abundance. D5R is highly expressed in cholinergic neurons in the
striatum and is involved in the induction of long-term potentia-
tion (LTP; Suzuki et al., 2001). Although present at low levels in
the striatum, the D3R receptor has approximately 200-fold higher
afﬁnity for dopamine than does D2R and is thought to be pri-
marily involved in regulating dopamine release at lower dopamine
concentrations (Joseph et al., 2002) by acting as an autoreceptor.
While little information about D4R is available, it is known to play
an important role in the regulation of striatal function because
genetic ablation impairs locomotor sensitization to cocaine and
amphetamine (Rubinstein et al., 1997; Kruzich et al., 2004; Thanos
et al., 2010).
Opioid receptors account for the actions of both endogenous
opioid peptides and exogenous opiates and are thought to be one
of the central molecular substrates that modulate reward signaling
in the striatum. Opioid receptors are involved in the modulation
of dopaminergic transmission in the striatum. Blockage of opioid
receptors, especially μ and δ, attenuates psychostimulant-induced
behavior sensitization (Heidbreder et al., 1993; Schad et al., 1996;
Balcells-Olivero and Vezina, 1997; Diaz-Otanez et al., 1997).
μopioid receptors are speciﬁcally enriched in striosomes and have
been shown to inhibit corticostriatal EPSCs (Jiang and North,
1992), and IPSCs (Miura et al., 2007), indicating that they play
a critical role in modulation of corticostriatal excitatory and
inhibitory synaptic transmission.μopioid receptors have also been
recently found to be expressed in a subset of cholinergic neurons
in the dorsal striatum, and activation of μopioid receptors inhibits
ACh release (Jabourian et al., 2005; Perez et al., 2007). κ and δ opi-
oid receptors in striatum were also shown to modulate dopamine
(Spanagel et al., 1992) and glutamate (Rawls and McGinty, 2000)
release and subsequently regulate stimulant-induced behavior
(Gray et al., 1999; Gonzalez-Nicolini et al., 2003).
Muscarinic receptors (mAChR) are expressed in the striatum in a
complex, overlapping manner where they mediate the slow-acting
response to Ach (Weiner et al., 1990; Levey et al., 1991; Bernard
et al., 1992; Hersch et al., 1994). The M1,M2, and M4 receptors are
the predominantmuscarinic receptors in the striatum (Levey et al.,
1991; Abrams et al., 2006). When activated, muscarinic receptors
modulate the excitability of striatal MSNs via the enhancement of
NMDA receptor-mediated currents (Calabresi et al., 1998a) or the
inhibition of voltage-activated N-, P-, and L-type Ca2+ currents
(Howe and Surmeier, 1995). Muscarinic receptors also modulate
the functions of striatal cholinergic interneurons; activation of M2
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and M4 receptors has been shown to inhibit both N- and P-type
Ca2+ currents (Yan and Surmeier, 1996). The inhibition of Ca2+
channels located at presynaptic sites ultimately leads to the inhi-
bition of ACh or glutamate release, which plays a crucial role in
coordinated changes in striatal neuronal activity (Calabresi et al.,
1998b; Rawls and McGinty, 1998). In addition, most mAChRs
are expressed in the terminals of dopaminergic neurons, where
they bidirectionally regulate dopamine release (Xu et al., 1989; De
Klippel et al., 1993; Smolders et al., 1997; Zhang et al., 2002).
Metabotropic glutamate receptors (mGluRs) modulate relatively
slow glutamate transmission through second messenger systems
(Nakanishi et al., 1998). mGluR1/5 are abundantly expressed post-
synaptically in the medium spiny projection neurons of the stria-
tum (Testa et al., 1995; Paquet and Smith, 2003). The activation
of group I mGluRs in MSNs induces synaptic plasticity by modu-
lating NMDA receptor activity (Pisani et al., 1997, 2001; Gubellini
et al., 2001, 2003; Swanson et al., 2001). Group II and group III
mGluRs are mostly located at presynaptic glutamatergic terminals
(Bradley et al., 1999; Kosinski et al., 1999; Tamaru et al., 2001;
Corti et al., 2002) and serve as autoreceptor decreasing glutamate
release (Cartmell and Schoepp, 2000; Schoepp, 2001).
In addition to these major GPCR players,many other receptors
expressed in this region are recognized to impact striatal signaling.
Two cannabinoid receptors (CB1 andCB2) have been characterized
to date. In the striatum, presynaptically expressed CB1 receptors
control both glutamate and GABA release in a retrograde manner
(Huang et al., 2001; Fernandez-Ruiz et al., 2002; Basavarajappa,
2007). Several G protein coupled serotonin (5-HT) receptors are
also expressed in the striatum and mediate diverse physiologi-
cal functions including modulation of stress response, depression,
and anxiety (Di Matteo et al., 2008; Nichols and Nichols, 2008).
Adenosine A2a receptors are highly enriched in the striatal neu-
rons, especially in the GABAergic striatopallidal neurons, where
adenosine A2a and dopamine D2 are colocalized (Fink et al.,
1992;Augood andEmson,1994). The physiological function of the
adenosineA2a receptor is characterizedby its antagonistic effect on
the dopamine D2 receptor, indicating a critical ﬁne-tuning effect
on indirect signaling pathway. There are several excellent reviews
of the basal ganglia functions of the adenosine A2a receptor (Fuxe
et al., 2007; Schiffmann et al., 2007).
In summary, the presence of multiple neurotransmitter recep-
tors in striatal neurons creates an environmentwheremanyGPCRs
signal to several effector molecules that uniquely control various
aspects of striatal function. At the same time, a tremendous inte-
gration of the signaling occurs downstream from the GPCRs as
many receptors share limited number of the effector molecules
ultimately responsible for generating responses in the striatum.
REGULATOR OF G PROTEIN SIGNALING PROTEINS: KEY
FOCAL POINTS OF THE REGULATORY INFLUENCE
The convergent organization of the G protein pathways suggests
that the factors that exert regulatory inﬂuence downstream from
the GPCR and upstream of the effector molecules provide univer-
sal control over the extent and duration of signaling and are key in
shaping cellular responses. Recent research has uncovered a num-
ber of proteins capable of altering the kinetics and dynamics of
G protein signal transduction (Ross and Wilkie, 2000; Siderovski
and Willard, 2005). Among these molecules, there has been sub-
stantial interest in proteins that facilitate termination of signaling,
providing a major opposing force to GPCR-driven activation.
Once activated, G proteins transmit the signal until GTP
hydrolysis occurs. G protein α subunits are inefﬁcient GTPases,
and their intrinsic inactivation takes up to several minutes. Nev-
ertheless, signaling termination in many well-studied G protein
pathways have been known to occur at substantially more rapid
timescales (Zerangue and Jan, 1998). While some effectors can
stimulate GTPase activity (Biddlecome et al., 1996; Paulssen et al.,
1996; Hart et al., 1998; Kozasa et al., 1998) and serve as GTPase
activating proteins (GAPs), these examples cannot account for
the entire range of signaling situations. Over the last decade,
it has become clear that the GAP function of heterotrimeric G
proteins is driven by a conserved family of proteins called regu-
lators of G protein signaling (RGS). RGS proteins associate with
the GTP-bound form of the Gα subunits and stabilize the tran-
sition state, dramatically accelerating GTP hydrolysis (Ross and
Wilkie, 2000). There are more than 30 members in the mam-
malian RGS family. They all share a conserved “catalytic” RGS
domain (∼130 amino acid residues) and are categorized into
six subfamilies (R4, RZ, R7, R12, RA, and RL) based on RGS
domain homology (Ross and Wilkie, 2000; Hollinger and Hep-
ler, 2002). It should be noted that not all RGS domains are
capable of accelerating GTP hydrolysis on G proteins. More-
over, for many RGS proteins, the relative efﬁciency of their GAP
function varies, depending on the identity of the Gα subunit
substrate.
In addition to the RGS domain, many RGS proteins possess
other, “non-catalytic” domains. Several functions of these non-
catalytic domains have been uncovered. First, they serve as regula-
tory elements for other signaling pathways (e.g., small GTPases),
endowing RGS proteins with multifunctionality in the regulation
of cellular signaling (Hart et al., 1998; De Vries and Gist Farquhar,
1999; Siderovski et al., 1999; Schiff et al., 2000; Willard et al.,
2007; Shu et al., 2010). Non-catalytic domains can also modify
the functions of the constituent catalytic domains of RGS pro-
teins by recruiting additional cellular factors and regulating their
GAP activity (Chen and Lin, 1998; Martemyanov et al., 2003a), G
protein selectivity (He et al., 2000; Martemyanov and Arshavsky,
2002), and localization (Srinivasa et al., 1998;DeVries et al., 2000b;
Martemyanov et al., 2003b).
During the last decade, the physiological functions of RGS pro-
teins in controlling a multitude of cellular reactions have been
extensively studied in a number of animal models by eliminat-
ing RGS protein function (Chen et al., 2000; Rahman et al., 2003;
Martin-McCaffrey et al., 2004; Sun et al., 2005; Cho et al., 2008;
Cifelli et al., 2008; Xie et al., 2008, 2010; Posokhova et al., 2010).
Phenotypic analysis varies, depending on the expression proﬁle
of the targeted RGS protein, and allows elucidation of the contri-
butions of RGS proteins to the regulation of cellular processes
and speciﬁc G protein pathways. One of the earliest examples
is RGS9-1, a short splice isoform of the RGS9 gene exclusively
expressed in photoreceptors of the retina (Martemyanov and
Arshavsky, 2009). In the absence of RGS9-1, inactivation of the G
protein transducin was shown to be severely delayed, causing dra-
matic delays in the deactivation of cellular responses to light (Chen
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et al., 2000). Another example is RGS2, a small, relatively ubiqui-
tous RGS protein that shows high selectivity for Gαq subunits
(Heximer, 2004). Given the importance of Gαq-coupled GPCRs
in the regulation of smoothmuscle tone, anRGS2 knockoutmodel
has been extensively evaluated in vascular systems and linked to
the development of hypertension (Heximer et al., 2003).
An alternative strategy to investigate the physiological functions
of endogenous RGS proteins is to create strains of mice carry-
ing RGS-insensitive (RGSi) G proteins (Lan et al., 1998; Jeong
and Ikeda, 2000; Huang et al., 2006; Talbot et al., 2010). This
approach is based on the introduction of a point mutation in the
Gα region that mediates RGS binding, rendering them insensitive
to the GAP actions of RGS proteins without affecting their inter-
actions with GPCRs and effectors (DiBello et al., 1998; Lan et al.,
1998). Genomic knock-in of RGSi G184S Gαi2 resulted in severe
dysfunctions in multiple organ systems, including the heart and
myeloid and central nervous systems (Huang et al., 2006; Talbot
et al., 2010).
RGS9-2, A KEY STRIATAL RGS PROTEIN WITH EFFECTS ON
DOPAMINE AND OPIOID SIGNALING
Perhaps one of themost studiedRGSproteins from the perspective
of striatal function is the long splice isoform of RGS9 (RGS9-2). It
ﬁrst attracted attention due to its selective enrichment in the stria-
tum (Gold et al., 1997;Thomas et al., 1998;Zhang et al., 1999). This
was followed by extensive behavioral studies in mice lacking RGS9
that ﬁrmly established RGS9-2 as the key player in many critical
aspects of striatal function. Speciﬁcally, RGS9 knockout mice dis-
play increased sensitivity to the reward and motor stimulatory
properties of addictive drugs, including cocaine and ampheta-
mine (Rahman et al., 2003; Zachariou et al., 2003). Elimination of
RGS9 exaggerates physical dependence on morphine;mice lacking
RGS9 showed heightened antagonist-precipitated withdrawal fol-
lowing chronic morphine administration (Zachariou et al., 2003).
Furthermore, knockout of RGS9 delayed the development of anal-
gesic tolerance to morphine (Zachariou et al., 2003), suggesting
that RGS9-2 also controls long-term adaptation responses that
adjust GPCR responsiveness following persistent stimulation and
may contribute to the molecular changes underlying addiction.
The changes in adaptive responses to drug administration in this
model do not seem to be limited to morphine. RGS9 knockouts
also display enhanced sensitization to repeated cocaine injections
(Rahman et al., 2003). In contrast, overexpression of RGS9 in
the striatum has the opposite effect and blunts responsiveness to
cocaine (Rahman et al., 2003).
Consistent with the importance of the striatum in motor con-
trol, the role of RGS9 in this process was also examined. RGS9-2
elimination was found to be detrimental to the coordination of
gross movements and led to delayed acquisition of motor learn-
ing in the rotarod test (Blundell et al., 2008; Anderson et al.,
2010). RGS9-2 also appears to play a critical role in control-
ling the development of dyskinesia, a disorder in which patients
involuntarily perform complex movements and which is often
triggered by chronic treatment with drugs targeting dopamine
signaling pathways (Rascol and Fabre, 2001; Jenner, 2008). RGS9
knockouts develop abnormal involuntary movements in response
to chronic treatment with either antipsychotics (Kovoor et al.,
2005) or l-DOPA in 6-OHDA model of Parkinson’s disease (Gold
et al., 2007) much more rapidly than wild type animals. In con-
trast, virus-mediated overexpression of RGS9-2 in the striatum
of 6-OHDA-treated rats and monkeys reduced the symptoms of
l-DOPA-induced dyskinesia (Gold et al., 2007). Because drug-
induced dyskinesia is a common debilitating side effect associ-
ated with many current anti-Parkinson’s and antipsychotic ther-
apies, RGS9-2 is an attractive candidate for the development of
pharmaceuticals aimed at ameliorating this condition.
Observations from mouse models are consistent with the
involvement of RGS9-2 in regulating motor and reward behav-
iors. These processes are controlled by dopamine and opioid
neurotransmitter systems (Hyman et al., 2006; Arbuthnott and
Wickens, 2007; Koob and Le Moal, 2008). Several groups have
investigated the role of RGS9-2 in regulating responses mediated
by dopamine and opioid receptors at the molecular and cellular
levels. Knockdown of RGS9-2 in vivo enhances the potency and
duration of antinociception mediated by μ-opioid, but not the
other opioid receptors (Sanchez-Blazquez et al., 2003). Similarly,
RGS9 knockout mice develop prominent involuntary movements
in response to D2R- but not D1R-selective agonists (Kovoor et al.,
2005). Further supporting the involvement of RGS9-2 in D2R
and μ-opioid actions, agonist-induced internalization of these
receptors is strongly inhibited by co-expression with RGS9-2 in
transfected cells (Psifogeorgou et al., 2007; Celver et al., 2010).
This regulation appears to be speciﬁc to RGS9-2 as RGS4 does not
have any appreciable effects on the internalization of D2R recep-
tors (Celver et al., 2010). This selectivity could be explained by
the formation of a macromolecular complex between RGS9-2 and
the receptors it regulates. Indeed, RGS9-2 coprecipitates with μ-
opioid from striatal lysates (Garzon et al., 2005a; Charlton et al.,
2008) and is recruited to the plasma membrane by co-expression
with D2R in transfected cells (Kovoor et al., 2005).
These ﬁndings imply that RGS9-2 is a negative regulator that
acts downstream of the D2R and μ-opioid in striatal neurons.
Both of these GPCRs are coupled to the inhibitory Gαi/o G pro-
teins. Consistent with this notion, biochemical studies conﬁrm
that RGS9-2 is a potent and selective GAP, acting primarily on
Gαo and, to a lesser extent, Gαi (Hooks et al., 2003; Martemyanov
et al., 2003a). In this context, it is worth noting that several other
Gαi/o-coupled GPCRs are expressed in striatal neurons and play
critical roles in striatal functions. It is possible that RGS9-2 is also
involved in regulating the responses of other Gαi/o GPCRs in this
region, acting as a general G protein signaling inhibitor. How-
ever, the speciﬁcity of RGS9-2 action in the striatum is virtually
unexplored and will need to be addressed in future studies.
The effectors regulated by RGS9-2 downstream from striatal
GPCRs have not been fully identiﬁed. Existing evidence points
to the involvement of RGS9-2 in the regulation of at least two
ion channels in the striatum: Cav2.2 and NMDAR. The intro-
duction of RGS9-2 into striatal cholinergic neurons reduced D2R
receptor-mediated modulation of Cav2.2 channels (Cabrera-Vera
et al., 2004). In striatal MSNs, knockout of RGS9 resulted in
augmentation of D2R-mediated suppression of NMDA currents
(Kovoor et al., 2005). Interestingly, RGS9-2 can physically bind to
NMDAR by association with the adaptor protein α-actin-2 to reg-
ulate Ca2+-dependent NMDAR inactivation (Bouhamdan et al.,
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2006). Because both μ-opioid and D2R are known to control a
variety of effector systems, it is possible that the role of RGS9-2
is not limited to the regulation of Cav2.2 and NMDAR chan-
nels. Indeed, RGS9-2 expression in transfected cells inhibits ERK
phosphorylation in response to μ-opioid activation (Psifogeorgou
et al., 2007). However, the full range of effector systems regulated
by RGS9-2 in striatal neurons remains to be established.
The regulatory inﬂuence exerted by RGS9-2 in striatal neurons
adjusts in response to changes in striatal signaling. Intriguingly,
the expression of RGS9-2 changes in response to activation of
signaling pathways that are normally regulated by RGS9-2. As dis-
cussed above, RGS9-2 regulates the extent of the effects produced
by cocaine and morphine. On the other hand, administration of
both cocaine andmorphine leads to changes inRGS9-2 levels in the
striatum. Acute morphine treatment increases, whereas chronic
exposure decreases, the RGS9-2 protein content in the mouse ven-
tral striatum (Zachariou et al., 2003; Psifogeorgou et al., 2007).
Chronic cocaine exposure increases RGS9-2 levels in the same
region (Rahman et al., 2003). RGS9-2 levels are also altered in
response to several other stimuli and some neuropathological con-
ditions. For example, repeated estradiol administration reduces
both RGS9-2 mRNA and protein levels in the shell of the nucleus
accumbens (Silverman and Koenig, 2007). RGS9-2 mRNA levels
were signiﬁcantly decreased in the striatum of a rat schizophrenia
model and in the brains of schizophrenia patients (Seeman et al.,
2007). RGS9-2 protein levels were elevated in the striata of Parkin-
son’s disease patients (Tekumalla et al., 2001). Finally, ischemia
and neuronal depolarization modeled in acutely cultured slices
also result in rapid downregulation of RGS9-2 (Anderson et al.,
2009a). Changes in RGS9-2 levels in response to RGS9-2-regulated
pathways may provide a mechanism for adaptive physiological
feedback, where the extent of regulation is adjusted based on the
volume of signaling.
At the molecular level, the regulation of RGS9 function is
achieved by controlling its association with auxiliary proteins.
RGS9-2 containsmultiple domains (Anderson et al., 2009b;Marte-
myanov and Arshavsky, 2009): the N-terminal DEP (Disheveled,
Egl-10, Pleckstrin) and DHEX (DEP helical extension) domains
are followed by the GGL (G protein γ-like) and C-terminal RGS
catalytic domains. The GGL domain binds to the type 5 Gβ sub-
unit (Gβ5). The DEP/DHEX module mediates the interaction of
R7RGSwith the anchor proteinR7BP (R7 family binding protein).
Both Gβ5 and R7BP simultaneously interact with RGS9-2 and are
considered bona ﬁde subunits within the complex. The knockout
of Gβ5 in mice results in severe downregulation of RGS9-2 in the
striatum (Chen et al., 2003). Similarly, levels of striatal RGS9-2
are dramatically reduced upon R7BP elimination (Anderson et al.,
2007b). Conversely, R7BP overexpression in the striatum leads to
the upregulation of RGS9-2 (Anderson et al., 2007a). In addition
to ensuring proteolytic stability of the RGS9-2 complex, R7BP also
controls the localization of RGS9-2 in the plasma membrane and
targets the postsynaptic dendrites of striatal neurons (Anderson
et al., 2007a).
Consistent with the roles of RGS9-2 in striatal functions and
R7BP in maintaining a high expression level of RGS9-2, elim-
ination of R7BP in mice results in a marked elevation in the
sensitivity to the motor-stimulation actions of opioids and deﬁcits
in motor coordination and learning that are similar to those
reported for RGS9-2 knockouts (Anderson et al., 2010). Inter-
estingly, the sensitivity of dopamine receptors to stimulation
remained unchanged in R7BP knockouts. These mice showed nor-
mal behavioral responses to cocaine, suggesting the existence of
selective compensatory mechanisms (Anderson et al., 2010) that
may involve other RGS proteins binding to R7BP. The behavioral
consequences and effects on striatal signaling due to the loss of
Gβ5 are largely unknown. Gβ5 knockout in mice alters the timing
of GABA(B)-mediated synaptic transmission in CA1 hippocam-
pal synapses (Xie et al., 2010), and similar deﬁcits may occur in
striatal neurons.
OTHER RGS PROTEINS IN THE STRIATUM
While severely affecting the levels of RGS9-2, the elimination of
R7BP does not reproduce the behavior of RGS9-2 knockouts, rais-
ing the possibility that other RGS proteins in the striatum can
bind to R7BP and be involved in controlling striatal signaling
in parallel with RGS9-2. Indeed, both R7BP and Gβ5 have been
shown to bind to RGS7. RGS7 belongs to the same R7 RGS family
as RGS9-2 and shares the same domain organization (Ander-
son et al., 2009a, 2010). Although critical for RGS9-2 stability,
R7BP is not necessary for RGS7 expression, as RGS7 protein levels
are unchanged in R7BP knockout mice (Anderson et al., 2007a,
2009a). Moreover, RGS9-2 couples to R7BP with an afﬁnity that
is an order of magnitude greater than that of RGS7, resulting in
a higher prevalence of RGS9-2/R7BP complexes when compared
to RGS7/R7BP, despite equal concentrations of both RGS9-2 and
RGS7 in striatal neurons (Anderson et al., 2009a). Elimination of
RGS9-2 changes this balance and results in marked upregulation
of R7BP/RGS7 complexes and their recruitment to postsynaptic
densities (Anderson et al., 2009a). Therefore, the higher sensitiv-
ity to cocaine observed in RGS9 knockout mice might involve the
alteration of RGS7 function, concurrent with the alteration of sig-
naling directly controlled by RGS9-2. Indeed, viral knockdown of
RGS7 in the striatum enhances behavioral sensitivity to cocaine
(Anderson et al., 2010).
Several other RGS family members, including RGS2, RGS4,
RGS10, and RGS17, are expressed in the striatum and play roles
in signal processing in this region. The interest in these members
is primarily driven by the observation that their expression levels
change in response to different stimuli,most prominently psychos-
timulants, suggesting that they are involved in neuronal plasticity
in this region. Speciﬁcally, RGS2 is rapidly induced in the striatum
in response to maximal electroconvulsive seizure stimulation that
evokes neuronal plasticity (Ingi et al., 1998). RGS2 is also upregu-
lated upon administration of amphetamine (Burchett et al., 1998,
1999; Ingi et al., 1998;Robinet et al., 2001).Amphetamine-induced
upregulation of RGS2 can be mimicked by D1 agonist adminis-
tration and blocked by the D1 receptor antagonist, SCH 23390
(Taymans et al., 2003). In contrast, a D2 antagonist, haloperidol,
upregulates RGS2 levels, whereas a D2 agonist, quinpirole, inhibits
its expression (Ingi et al., 1998; Burchett et al., 1999; Taymans et al.,
2003). Thus, D1 and D2 dopamine receptors play an antagonis-
tic role in modulating the abundance of RGS2. RGS4 is another
protein that belongs to the same R4 subfamily and shows promi-
nent signal-dependent regulation of expression in the striatum.
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Its levels are generally downregulated by the excess dopamine pro-
duced by amphetamine (Gonzalez-Nicolini and McGinty, 2002;
Schwendt et al., 2006) or cocaine (Zhang et al., 2005a; Schwendt
et al., 2007) and upregulated when dopamine is depleted (e.g., in a
Parkinson’s model; Geurts et al., 2002, 2003; Taymans et al., 2003;
Zhang et al., 2005b; Ding et al., 2006). Interestingly, modulation
of RGS4 expression levels has been linked to behavioral sensi-
tization in response to repeated psychostimulant administration
(Schwendt and McGinty, 2007) and upregulation of acetylcholine
release with Parkinson’s due to decreased autoinhibition of the
striatal cholinergic interneurons (Ding et al., 2006). The molecu-
lar details of the RGS2 and RGS4 actions are beginning to emerge.
Both RGS proteins are potent negative modulators of Gαq sig-
naling and affect signaling downstream from mGluR5 receptors,
inﬂuencing synaptic plasticity (Schwendt and McGinty, 2007).
In addition, RGS4 and, to a lesser extent, RGS2 are capable of
controlling G protein signaling downstream from Gαi/o-coupled
receptors. By this action, RGS4 serves as an inhibitor of M4
autoreceptors in striatal cholinergic neurons and μ-opioid recep-
tors in the nucleus accumbens (Ding et al., 2006; Han et al.,
2010). RGS2 was also shown to modulate synaptic vesicle release
by controlling Gαi/o-mediated presynaptic Ca2+ channel inhibi-
tion (Han et al., 2006). RGS2 has additional GAP-independent
effects that directly inhibit AC activity (Sinnarajah et al., 2001).
However, the role of this striatal signaling mechanism remains
unexplored.
Among other striatal RGS proteins, RGS17 (Stanwood et al.,
2006) is upregulated in the nucleus accumbens by ontogenetic
treatment with the D2R agonist, quinpirole (Maple et al., 2007),
and has been shown to regulate three different neurotransmit-
ter systems, including muscarinic M2, μ-opioid, and dopamine
D2 receptors (Mao et al., 2004; Garzon et al., 2005b). Finally,
RGS10 is enriched in microglia where it regulates the expression
of inﬂammation-related genes (Lee et al., 2008). By regulating
the survival of dopaminergic neurons in the substantia nigra,
RGS10 plays a critical role in setting the dopaminergic tone in the
striatum, the central target nucleus innervated by dopaminergic
neurons (Lee et al., 2008).
NOVEL PROTEINS INFLUENCING G PROTEIN CYCLE AND
THEIR EMERGING ROLES IN THE STRIATUM
Regulator of G protein signaling proteins could be viewed as
general inhibitors of G protein signaling because they negatively
regulate both Gα and Gβγ subunit signaling. In recent years, there
has been an explosion of research on protein factors that affect G
protein signaling at the same universal focal points as RGS pro-
teins but exert differential effects on the activation of G protein
subunits. Overall, these proteins can be separated into two groups.
The ﬁrst group is represented by molecules with guanine disso-
ciation inhibitor (GDI) activity that stabilize Gα in the inactive
GDP-bound form, preventing spontaneous and GPCR-dependent
activation (Ma et al., 2003; Willard et al., 2004). At the same time,
binding of GDI proteins to Gα–GDP inhibits reassociation with
βγ, promoting βγ-selective signaling. All known GDI proteins
contain a G protein regulatory (GPR, also known as GoLoco)
domain that speciﬁcally binds and stabilizes Gα–GDP (Kimple
et al., 2002; Natochin et al., 2002). Among several GDI proteins,
AGS3 is known tohave effects on striatal signaling by regulating the
activation and deactivation of the Gαi protein and associated βγ
subunits (Takesono et al., 1999; DeVries et al., 2000a). AGS3 levels
are upregulated during withdrawal from chronic cocaine (Bowers
et al., 2003, 2004) and morphine (Fan et al., 2009) administra-
tion. In accordance with these observations, knockdown of AGS3
prevents cAMP superactivation during morphine withdrawal in
the rat nucleus accumbens neurons (Peterson et al., 2000; Fan
et al., 2009). Finally, introduction of AGS3 GPR motifs in vivo
prevent Gαi signaling and promote drug seeking and locomotor
sensitization (Bowers et al., 2004).
The second group of G protein regulators with emerging
striatal functions is represented by proteins that catalyze GPCR-
independent activation of G protein α subunits. These proteins
act as a GEF for the Gα subunit by interacting with GDP-bound
α subunits in the absence of βγ. They were initially discov-
ered in mutant screens and suppression assays in C. elegans and
termed RIC (resistant to inhibitors of cholinesterase; Miller et al.,
1996; Hajdu-Cronin et al., 1999). Mammalian homologs of Ric-8,
termedRic-8A andRic-8B,were found through a yeast two-hybrid
screen with Gαo as bait (Tall et al., 2003) and shown to be a pow-
erful GEF for the Gα subunits. Although the role of Ric-8A in
the striatum has not been addressed speciﬁcally, initial evidence
indicates that this protein serves as a modulator of both AGS3
(Thomas et al., 2008) and AC5 (Wang et al., 2007), suggesting its
involvement in key steps of striatal signaling.
In conclusion,emergingpicture indicates that numerousGpro-
tein pathways in the striatum are controlled by the host of the
regulatory proteins, that affect the dynamics of signaling in the
region and thus play critical roles in shaping behavioral responses
mediated by the striatal neurons.
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